



**THE WORLD'S PREMIER RETINA MEETING**



**ASRS 40<sup>TH</sup> ANNUAL  
SCIENTIFIC MEETING**

July 13 - 16, 2022

New York, NY

**WEDNESDAY, JULY 13**

<b>3:30-5:30 PM</b>	<b>Retina Case Conference</b> Moderator: Dean Elliott, MD  Vishal Agrawal, MD, FRCS, FACS, FASRS Nikhil Batra, MD Kevin Blinder, MD, FASRS Daniel Brill, MD Avni Finn, MD, MBA Ronald Gentile, MD R. Rishi Gupta, MD Srinivas Joshi, MD, FASRS M. Ali Khan, MD, FACS, FASRS Jaclyn Kovach, MD Brian Lee, MD Jong Park, MD Prethy Rao, MD, MPH Ahmad Rehmani, DO Lincoln Shaw, MD Bradley Smith, MD, FASRS Manju Subramanian, MD Eduardo Uchiyama, MD, FACS, FASRS Lejla Vajzovic, MD, FASRS Nita Valikodath, MD, MS Taku Wakabayashi, MD Jay Wang, MD Christina Weng, MD, MBA, FASRS David Xu, MD Yoshihiro Yonekawa, MD, FASRS
---------------------	--

**6:30-10:00 PM**    **Opening Reception at Cipriani**

**THURSDAY, JULY 14**

**7:30-8:30 AM**    **Continental Breakfast**

**8:00-8:10 AM**    **Opening Comments**

<b>8:10-9:00 AM</b>	<b>Wet AMD 1 Symposium</b> Moderators: Judy Kim, MD, FASRS and Sophie Bakri, MD
8:10 AM	Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity, <b>Justis Ehlers, MD, FASRS</b>
8:14 AM	Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials, <b>Arshad Khanani, MD, MA, FASRS</b>
8:20 AM	UBX1325, A Novel Senolytic Therapy for Treatment-Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study, <b>Raj Maturi, MD</b>
8:24 AM	Discussion
8:36 AM	Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring, <b>Michael Elman, MD</b>
8:40 AM	Conversion Rates from Nonexudative to Exudative Age-Related Macular Degeneration: An AAO IRIS® Registry Analysis, <b>Dan Gong, MD</b>
8:46 AM	Subretinal Pneumatic Displacement Without Tissue Plasminogen Activator for Submacular Hemorrhage: One-year Outcomes, <b>Marwan Abdulaal, MD</b>
8:50 AM	Discussion

---

<b>9:00-9:30 AM</b>	<b>Dry AMD 1 Symposium</b> Moderators: <b>Jeffrey Heier, MD</b> and <b>Caroline Baumaal, MD</b>
9:00 AM	ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy, <b>Jeffrey Heier, MD</b>
9:06 AM	Assessment of Geographic Atrophy Lesion Progression in the Phase 3 OAKS and DERBY Trials, <b>Roger Goldberg, MD, MBA</b>
9:10 AM	Association Between Dysfunctional Complement Factor I: Rare Variant Status and Progression to Advanced AMD Outcomes, <b>Johanna Seddon, MD, ScM</b>
9:16 AM	Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials, <b>Caroline Baumaal, MD</b>
9:20 AM	Discussion

---

<b>9:30-10:10 AM</b>	<b>Break</b>
----------------------	--------------

---

<b>10:10-11:10 AM</b>	<b>Diabetic Retinopathy 1 Symposium</b> Moderators: <b>Jennifer Lim, MD, FARVO, FASRS</b> and <b>Joel Pearlman, MD, PhD</b>
10:10 AM	Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema, <b>Chirag Jhaveri, MD, FASRS</b>
10:16 AM	Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials, <b>David Eichenbaum, MD, FASRS</b>
10:22 AM	Randomized Phase 1 Trials of RZ402, a Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Edema, <b>Robert Bhisitkul, MD, PhD</b>
10:26 AM	Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema, <b>Karl Csaky, MD, PhD</b>
10:32 AM	Discussion
10:42 AM	Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy, <b>Michael Allingham, MD, PhD</b>
10:46 AM	Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post Fac, <b>Christopher Riemann, MD</b>
10:50 AM	Investigating the Utility of Near-Infrared Reflectance Imaging for Diabetic Retinopathy Screening, <b>Mina Naguib, MD</b>
10:54 AM	Progressive Quantitative Outer Retinal Optical Coherence Tomography Abnormalities in Early Diabetic Retinopathy Compared with Controls, <b>Jennifer Lim, MD, FARVO, FASRS</b>
11:00 AM	Discussion

---

<b>11:10 AM-12:05 PM</b>	<b>Surgery Symposium 1</b> Moderators: <b>Maria Berrocal, MD</b> and <b>Gaurav Shah, MD</b>
11:10 AM	Visual Outcomes and Complications of Combined vs Sequential Cataract Surgery and Pars Plana Vitrectomy: Multicenter Database Study, <b>Ahmed Sallam, MD, PhD, FRCOPath</b>
11:16 AM	Retinal Displacement After Scleral Buckle vs Combined Scleral Buckle and Vitrectomy for the Management of Rhegmatogenous Retinal Detachment: ALIGN SB vs PPV-SB, <b>Aditya Bansal, MD</b>

---

11:20 AM	Randomized Controlled Trial of Perioperative Intravenous Dexamethasone on Postoperative Analgesia in Scleral Buckle Surgery, <b>Jonathan Prenner, MD</b>
11:26 AM	Surgical Outcomes of Combined Pars Plana Vitrectomy and Scleral Fixation of Intraocular Lenses: Comparison of Gore-Tex Suture vs Intrasceral Haptic Fixation, <b>David Xu, MD</b>
11:32 AM	Discussion
11:41 AM	Study of Simulated Vitreoretinal Performance After Multimodal Pharmacological and Behavioral Exposures Among Surgeons With Varying Levels of Surgical Experience, <b>Mitchell Wolf, MD, PhD</b>
11:47 AM	Retinal Massager: New Multifunctional Tool for Vitrectomy, <b>Manish Nagpal, MD, FRCS (UK), FASRS</b>
11:51 AM	Surgical Outcomes of Scleral Buckling for Rhegmatogenous Retinal Detachment Using the NGENUITY 3-Dimensional Visualization System With a Guarded Light Pipe, <b>John Miller, MD</b>
11:57 PM	Discussion

<b>12:05-1:20 PM</b>	<b>CONCURRENT SESSIONS</b>
	<b>General Lunch</b>
	<b>Fellowship Directors Lunch</b>
	<b>Instructional Course: ASRS Research and Therapeutics (ReST) Committee Symposium—Clinical Trials “Unplugged”—Real, Practical Questions and Answers</b> Course Director: <b>Peter Kaiser, MD, FASRS</b>
	<b>Instructional Course: Vitreoretinal Surgical Rounds</b> Course Director: <b>Paul Hahn, MD, PhD, FASRS</b>

<b>1:20-2:25 PM</b>	<b>Surgery Symposium 2</b> Moderators: <b>Eric Nudelman, MD, PhD</b> and <b>Aleksandra Rachitskaya, MD, FASRS</b>
1:20 PM	Multilayered Inverted Internal Limiting Membrane Flap Technique vs Standard Internal Limiting Membrane Peeling for Large Macular Holes: Comparative Study <b>Vishal Agrawal, MD, FRCS, FACS, FASRS</b>
1:26 PM	Pars Plana Vitrectomy for Symptomatic Vitreous Opacities: Large Multicenter Case Series, <b>Samuel Houston, MD, FASRS</b>
1:30 PM	Epiretinal Human Amniotic Membrane Grafting for Complex Surgical Macular Pathologies, <b>Tongalp Tezel, MD</b>
1:36 PM	Scleral Imbrication and Fovea-Sparing ILM Peel as a Treatment for Myopic Foveoschisis, <b>Fong May Chew, FRCOphth, MBBS, BSc</b>
1:42 PM	Discussion
1:50 PM	Endophthalmitis After Pars Plana Vitrectomy Without Postoperative Topical Antibiotics, <b>Tahsin Khundkar, MD</b>
1:54 PM	Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials, <b>Glenn Yiu, MD, PhD</b>
2:00 PM	Vitreoretinal Biopsy Techniques and the Role of Retinal Biopsy in Vitreoretinal Lymphoma: Single-Institution Experience, <b>Sunil Srivastava, MD</b>
2:06 PM	State of Pediatric Retinal Detachment Surgery in the United States: An Aggregated Electronic Health Record Analysis of 2200 Children, <b>Yoshihiro Yonekawa, MD, FASRS</b>

2:12 PM	Cutter-Based vs Forceps-Based Membrane Peeling for Removal of Epimacular Membranes <b>Scott Walter, MD, MSc</b>
2:16 PM	Discussion

---

**2:25-3:00 PM      Imaging, Digital, Angiography Symposium**  
Moderators: **Szilard Kiss, MD** and **Fabio Patelli, MD**

2:25 PM	Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography: Observational Cohort Study, <b>Young Hee Yoon, MD, PhD</b>
2:31 PM	Level of Diabetic Retinopathy Severity Correlates to Degree of Quadrant Asymmetry in Both Single and Averaged Imaged OCTA Metrics, <b>Jesse Jung, MD, FASRS</b>
2:35 PM	Retinal Displacement On Fundus Autofluorescence Imaging: Only The Tip Of the Iceberg, <b>Koby Brosh Heshin, MD, MHA</b>
2:39 PM	Discussion
2:46 PM	Infrared Video for the Demonstration and Quantification of Macula-Involving Symptomatic Vitreous Opacities, <b>Shawn Kavoussi, MD</b>
2:50 PM	Regression Patterns of Central Serous Chorioretinopathy Using En Face Optical Coherence Tomography, <b>Supriya Arora, MS</b>
2:54 PM	Discussion

---

**3:00-3:40 PM      Break**

---

**3:40-4:10 PM      Socioeconomic Panel**  
Moderator: **Reginald Sanders, MD**

---

**4:10-5:00 PM      Inflammatory & Infectious Diseases Symposium**  
Moderators: **Sunil Srivastava, MD** and **Dimosthenis Mantopoulos, MD, PhD**

4:10 PM	Biomarkers in the Vitreous Humor Correlate With Alzheimer's Disease and Chronic Traumatic Encephalopathy in Postmortem Eyes and Brain, <b>Manju Subramanian, MD</b>
4:16 PM	Association of OCT Choroidal Thickness Maps and Automated Fixed-Depth Intensity Maps With Disease Activity in Birdshot Chorioretinopathy, <b>Keirnan Willett, MD</b>
4:20 PM	Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis, <b>Christopher Henry, MD</b>
4:24 PM	Discussion
4:31 PM	Ultra-Widefield Fluorescein Angiography and OCT Findings in Children and Young Adults With Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy, <b>Arjun Sood, MD</b>
4:35 PM	Heterogeneous Presentations of De Novo and Recurrent Uveitis After COVID-19 Vaccination: Multicenter Report, <b>Sruthi Arepalli, MD</b>
4:41 PM	Ocular Involvement in Candidemia Diagnosed by T2 vs Blood Culture With Recommendations on Screening for Endogenous Candida Endophthalmitis, <b>John Mason, MD</b>
4:47 PM	Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Uveitis: Integrated Analysis of 2 Clinical Trials, <b>Steven Yeh, MD</b>
4:53 PM	Discussion

---

<b>5:00-5:55 PM</b>	<b>Surgery Symposium 3</b> Moderators: <b>Paul Hahn, MD, PhD, FASRS</b> and <b>Dean Elliott, MD</b>
5:00 PM	Opportunity Cost of Vitreoretinal Surgeries <b>Ella Leung, MD</b>
5:04 PM	Economic Impact of Retina Procedure Volume Changes Due to the COVID-19 Pandemic: Analysis of 2020 Medicare Data, <b>Shriji Patel, MD, MBA</b>
5:08 PM	Feature Tracking and Image Segmentation in Real Time via Deep Learning in Vitreoretinal Surgery: Framework for AI-Mediated Surgical Guidance, <b>Yannek Leiderman, MD, PhD</b>
5:14 PM	Novel Technique for Capsular Tension Ring Explantation With Concomitant Intraocular Lens Exchange, <b>Howard Fine, MD, MHSc</b>
5:18 PM	Discussion
5:26 PM	Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry, <b>Sunir Garg, MD, FACS, FASRS</b>
5:32 PM	Timing of Delayed Retinal Pathology in Patients Presenting With Acute Posterior Vitreous Detachment in the IRIS Registry, <b>Gautam Vangipuram, MD</b>
5:36 PM	Incidence and Risk Factors for Rhegmatogenous Retinal Detachment After Cataract Surgery: Analysis of the American Academy of Ophthalmology IRIS Registry, <b>M. Ali Khan, MD, FACS, FASRS</b>
5:40 PM	Two-Year Evaluation of Subretinal Fluid Drainage Techniques in Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment (ELLIPSOID-2 Study), <b>Bryon McKay, MD, PhD, FRCSC</b>
5:46 PM	Discussion
<b>6:00-7:00 PM</b>	<b>Scientific Poster Q&amp;A and Exhibit Hall Reception</b>
<b>7:00-8:00 PM</b>	<b>Fellows-in-Training Reception</b>

---

---

**FRIDAY, JULY 15**


---

**7:30-8:30 AM Continental Breakfast**


---

**8:00-9:00 AM Wet AMD 2 Symposium**

 Moderators: **Anat Lowenstein, MD** and **Charles Wykoff, MD, PhD, FASRS**

- 8:00 AM Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database, **Anita Barikian, MD**
- 8:04 AM AI-Based Spatiotemporal Observations of Retinal Fluid Dynamics Using the Notal Vision Home OCT, **Anat Loewenstein, MD**
- 8:10 AM Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the PDS, **Veeral Sheth, MD, MBA, FASRS, FACS**
- 8:16 AM ADVIM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update, **Dante Pieramici, MD**
- 8:22 AM Discussion
- 8:31 AM End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD, **Aleksandra Rachitskaya, MD, FASRS**
- 8:37 AM Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand (TOWER) Study Report No. 2: The Fluid Analysis, **Yodpong Chantarasorn, MD**
- 8:41 AM Long-Term Use of Antivascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration, **Tedi Begaj, MD**
- 8:47 AM Prophylactic Intraocular Pressure-Lowering Measures in Antivascular Endothelial Growth Factor Therapy: Systematic Review and Meta-Analysis, **Parnian Arjmand, MD, MSc, FRCSC**
- 8:51 AM Discussion
- 

**9:00-9:55 AM Dry AMD 2 Symposium**

 Moderators: **Marco Zarbin, MD, PhD** and **Johanna Seddon, MD, ScM**

- 9:00 AM Inhibition of C1q Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy, **Patrick Williams, MD**
- 9:06 AM Platform for Screening Compounds for Treatment of AMD Using iPSC-derived Human RPE: Examples Using Elamipretide and SBT-272, **Lucian Del Priore, MD, PhD**
- 9:12 AM Screening Mitochondrial-Targeted Drugs in iPSC-RPE from Patients With Dry Age-Related Macular Degeneration, **Sandra Montezuma, MD, FASRS**
- 9:16 AM Association of Metformin and Other Antidiabetic Medication Use with Risk of Age-Related Macular Degeneration, **Dimitra Skondra, MD, PhD**
- 9:20 AM Discussion
- 9:30 AM Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years, **Ehsan Rahimy, MD**
- 9:36 AM Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis, **Durga Borkar, MD**
-

9:42 AM	Long-Term Effects of Hydroxychloroquine Therapy on Choroidal Volume and Choroidal Vascularity Index, <b>Nasiq Hasan, MD</b>
9:46 AM	Discussion
<b>9:55-10:25 AM</b>	<b>JVRD “Best of the First 6 Years” Panel</b> Moderator: <b>Donald J. D’Amico, MD</b> Speakers: <b>John Hinkle, MD</b> <b>Matthew Sapp, MD</b> <b>Steven Yeh, MD</b> <b>Timothy Murray, MD, MBA, FASRS</b>
<b>10:25-11:05 AM</b>	<b>Break</b>
<b>11:05 AM-12:30 PM</b>	<b>Awards Ceremony</b> Moderators: <b>Jonathan Prenner, MD</b> and <b>Philip Ferrone, MD, FASRS</b>
11:05 AM	2022 Pyron Award Introduction
11:07 AM	2022 Pyron Award, <b>Mary Elizabeth Hartnett, MD, FACS, FARVO, FASRS</b>
11:20 AM	2021 Founders Award Introduction
11:22 AM	2021 Founders Award, <b>Stanislao Rizzo, MD</b>
11:35 AM	2022 Founders Award Introduction
11:37 AM	2022 Founders Award, <b>Maria Berrocal, MD</b>
11:50 AM	Early Career Section (ECS) Crystal Apple Awards Presentation to <b>Sharon Fekrat, MD, FACS, FASRS</b>
11:55 AM	ASRS Presidents’ Retina Young Investigators Award Introduction
11:57 AM	ASRS Presidents’ Retina Young Investigators Award, <b>Justis Ehlers, MD, FASRS</b>
12:05 PM	Packo Award Presentation to <b>Suber Huang, MD, MBA, FASRS</b>
12:15 PM	Retina Image Bank Award
12:20 PM	Retina Hall of Fame Award
<b>12:30-1:45 PM</b>	<b>CONCURRENT SESSIONS</b>
	<b>General Lunch</b>
	<b>Early Career Section Lunch</b>
	<b>Instructional Course: OCT Angiography in Clinical Practice</b> Course Director: <b>Caroline Baumal MD</b>
	<b>Instructional Course: How Imaging Helped Me Nail the Diagnosis—Cases From The Experts</b> Course Director: <b>Yasha Modi, MD</b>
<b>1:45-1:55 PM</b>	<b>Business Meeting</b>
<b>1:55-2:05 PM</b>	<b>PAT Survey and Global Trends</b>
<b>2:05-3:05 PM</b>	<b>Diabetic Retinopathy 2 Symposium</b> Moderators: <b>Carl Regillo, MD</b> and <b>Young Hee Yoon, MD, PhD</b>



- 2:05 PM Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of DR Worsening Over Time: Results of DRCR Retina Network Protocol AA, **Dennis Marcus, MD**
- 2:09 PM Utilization, Payments, and Effectiveness of Teleophthalmology for Remote Diabetic Eye Screening in the US, **Parisa Emami Naeini, MD, MPH**
- 2:13 PM New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus, **Bobek Modjtahedi, MD**
- 2:17 PM Long-Term Real-World Treatment Patterns Among Patients With Diabetic Macular Edema Initiating Anti-VEGF: 6-year Follow-up Using the IRIS Registry, **Theodore Leng, MD, MS, FASRS**
- 2:21 PM Discussion
- 2:30 PM Brolucizumab for the Treatment of Diabetic Macular Edema: 52-week Results from the KINGFISHER Study, **Rishi Singh, MD**
- 2:36 PM Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study, **Charles Wykoff, MD, PhD, FASRS**
- 2:42 PM Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema, **John Kitchens, MD**
- 2:48 PM Association of Ultra-Widefield Fluorescein Angiography-identified Retinal Nonperfusion With Risk of Diabetic Retinopathy Worsening Over Time, **Paolo Antonio Silva, MD**
- 2:52 PM Treat-and-Extend vs Alternate Dosing Strategies With Anti-VEGF Agents to Treat Center-Involving Diabetic Macular Edema: Meta-Analysis of Trials, **Varun Chaudhary, MD**
- 2:56 PM Discussion
- 
- 3:05-4:00 PM Surgery Symposium 4**  
Moderators: **Carl Awh, MD, FASRS** and **Stanislao Rizzo, MD**
- 3:05 PM Fibrin Glue-Assisted Retinopexy for Rhegmatogenous Retinal Detachments: GUARD Study; Long-Term Outcomes of a New Surgical Technique With No Silicone Oil or Gas Tamponade, **Mudit Tyagi, MS**
- 3:11 PM Intravitreal Methotrexate Reduces Reoperation Rate and Improves Vision After Vitrectomy for Retinal Detachment, Trauma, and Proliferative Diabetic Retinopathy, **Alan Franklin, MD, PhD**
- 3:17 PM Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study, **Sally Ong, MD**
- 3:23 PM Long-Term Visual Outcomes of Fovea-Splitting Rhegmatogenous Retinal Detachments, **Jeremy Wolfe, MD, MS**
- 3:27 PM Discussion
- 3:35 PM Clinical Outcomes After Repair of Primary Acute Rhegmatogenous Retinal Detachment With Scleral Buckle, **Sushant Wagley, MD**
- 3:39 PM Outcomes of Pars Plana Vitrectomy Alone vs Combined Scleral Buckling Plus Pars Plana Vitrectomy for Primary Retinal Detachment, **Luis Haddock, MD**

3:43 PM	Clinical Outcomes of Rhegmatogenous Retinal Detachment Repair in Pseudophakic Eyes With Multifocal Intraocular Lenses, <b>Abtin Shahlaee, MD</b>
3:47 PM	Impact of Foveal Status and Timing of Surgery on Visual Outcome in Rhegmatogenous Retinal Detachment, <b>Zeeshan Haq, MD</b>
3:53 PM	Discussion

---

**4:00-4:40 PM Break**


---

**4:40-5:25 PM Ocular Oncology Symposium**

 Moderators: **Basil Williams, MD** and **Amy Scheffler, MD, FACS, FASRS**

4:40 PM	Early Targeted Treatment for Uveal Melanoma Markedly Reduces Mortality: Evaluation of a Large Cohort of Class 2 GEP-Treated Small Ocular Melanoma Patients, <b>Timothy Murray, MD, MBA, FASRS</b>
4:46 PM	Likelihood of Germline Mutation With Solitary Unilateral Retinoblastoma Based on Patient Age at Presentation: Real-World Analysis of 482 Consecutive Patients, <b>Carol Shields, MD</b>
4:52 PM	Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2), <b>Prithvi Mruthyunjaya, MD, MHS</b>
4:58 PM	Discussion
5:04 PM	Clinical Features in Advanced Retinoblastoma: High-Risk Pathology and Metastatic Death, <b>Paul Finger, MD, FACS</b>
5:10 PM	Application of a Novel Semi-Supervised Machine Learning Approach to Identify Choroidal Tumors From Fundus Photographs, <b>Armin Afshar, MD, MBA, MAS</b>
5:14 PM	Gene Expression Profile and Local Tumor Recurrence of Irradiated Uveal Melanomas, <b>Basil Williams, MD</b>
5:18 PM	Discussion

---

**5:25-5:55 PM Surgery Symposium 5**

 Moderators: **Tarek Hassan, MD, FASRS** and **Lisa Olmos de Koos, MD, MBA**

5:25 PM	Factors Associated With COVID-19 Vaccine Hesitancy and Clinical Trends in the Presentation of Primary Rhegmatogenous Retinal Detachments, <b>Peter Tang, MD, PhD</b>
5:29 PM	Giant Retinal Detachment: Etiologies, Clinical Presentation, and Treatment Outcomes, <b>Vishal Raval, MBBS, DNB, FMRF, FASRS</b>
5:33 PM	Fellow-Eye Retinal Detachment Risk as Stratified by Hyaloid Status on Optical Coherence Tomography, <b>Josh Wallish, MD</b>
5:39 PM	Multimodal Imaging Predictors of Functional Outcomes Following Rhegmatogenous Retinal Detachment Repair, <b>Wei Wei Lee, MD</b>
5:45 PM	Discussion

---

**5:55-6:15 PM**

**Technology**

Moderators: **Ehab El-Rayes, MD, PhD, FASRS**  
and **Yannek Leiderman, MD, PhD**

5:55 PM

Evaluation of a Robotically Aligned Optical Coherence Tomography System and Artificial Intelligence in Patients from the Emergency Department, **Nita Valikodath, MD, MS**

5:59 PM

Real-Time Diagnosis of Diabetic Retinopathy by a Handheld Retinal Camera, Artificial Intelligence and Simultaneous Specialist Confirmation: Closing the Gap, **Gustavo Melo, MD, PhD, FASRS**

6:03 PM

Smartphone-Based Home Vision Monitoring: Enablers and Barriers to Deployment in Clinical Practice Settings, **Edward Korot, MD**

6:07 PM

Discussion

---

**6:15-7:45 PM**

**WinR Case Conference**

---

**SATURDAY, JULY 16**


---

**7:30-8:30 AM Continental Breakfast**


---

**8:00-9:35 AM Retinal Vascular Disease Symposium**

 Moderators: **Dante Pieramici, MD** and **Sharon Fekrat, MD, FACS, FASRS**

- 8:00 AM Subclinical Retinal Ischemia in Individuals With Atrial Fibrillation **Mathieu Bakhoum, MD, PhD**
- 8:06 AM Point of Care Diagnosis of CRAO With OCT at the Stroke Center: Lessons Learned in Our First Year, **Gareth Lema, MD, PhD**
- 8:12 AM Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials, **Dilsher Dhoot, MD**
- 8:16 AM Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MErVO) Comparing Dexamethazone vs Anti-VEGF Therapy, **John Huang, MD**
- 8:20 AM Discussion
- 8:30 AM Longitudinal Macular Thickness and Microvascular Changes in Children with Sickle Cell Disease, **Adrienne Scott, MD, FASRS**
- 8:36 AM Spatial Correlation Between Retinal Ischemia and Reactive Choroidal Changes in Retinal Vein Occlusion, **Junyeop Lee, MD, PhD**
- 8:40 AM Predicting Outcomes and Treatment Frequency After Monthly Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: A Machine-Learning Model Approach, **Yasha Modi, MD**
- 8:46 AM Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes, **Amy Scheffler, MD, FACS, FASRS**
- 8:52 AM Discussion
- 9:01 AM Characterization of Vascular Abnormalities in X-Linked Retinoschisis Using Widefield Digital Fluorescein Angiography, **Audina Berrocal, MD FASRS**
- 9:07 AM National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity, **Nimesh Patel, MD**
- 9:11 AM Long-Term Follow-up of Patients Treated With Laser for Retinopathy of Prematurity, **Rita Ehrlich, MD**
- 9:15 AM Modeling Zone as a Proxy for Absolute Avascular Retina Area and Retinopathy of Prematurity Risk, **Darius Moshfeghi, MD, FASRS**
- 9:21 AM Rate of and Time for Complete Retinal Vascularization in Premature Infants and Its Associated Factors, **Tso-Ting Lai, MD**
- 9:25 AM Discussion

---

**9:35-10:15 AM Break**


---

**10:15-11:20 AM Dry AMD 3 Symposium**

 Moderators: **Neil Bressler, MD** and **Susan Bressler, MD, FASRS**

- 10:15 AM Assessment of the Inclusion of Racial/Ethnic Minorities in Retina Clinical Trials, **Vivienne Hau, MD, PhD**

10:21 AM	Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis), <b>Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO</b>
10:27 AM	Preliminary Results from a Phase I/II Gene Therapy (FOCUS) of Subretinally Delivered GT005 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration, <b>Szilárd Kiss, MD</b>
10:33 AM	Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients With Advanced Retinitis Pigmentosa, <b>Peter Kaiser, MD, FASRS</b>
10:39 AM	Discussion
10:49 AM	Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy, <b>Glenn Jaffe, MD</b>
10:55 AM	Early Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study, <b>David Lally, MD</b>
10:59 AM	Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials, <b>Eleonora Lad, MD, PhD</b>
11:03 AM	Could We Save Lives With Retinal Imaging by Finding Undetected High-Risk Vascular Diseases?, <b>R. Theodore Smith, MD PhD</b>
11:09 AM	Discussion

**11:20-11:50 AM      Surgery Panel**  
**J. Michael Jumper, MD, FASRS**

**11:50 AM-1:05 PM      CONCURRENT SESSIONS**

**General Lunch**

**Women in Retina Lunch**

**Instructional Course: Running the Gauntlet: Innovations in the Surgical Management of Uveitis**  
 Course Director: **Steven Yeh, MD**

**Instructional Course: RETINAWAS: When the Going Gets Tough, the Tough Get Going, Challenging Cases in Vitreoretinal Surgery**  
 Course Director: **Kourous Rezaei, MD**

<b>1:05-1:50 PM</b>	<b>Diabetic Retinopathy 3 Symposium</b> Moderators: <b>Jennifer Sun, MD</b> and <b>Francesco Boscia, MD</b>
1:05 PM	Efficacy, Safety, and Immunogenicity of MYL-1701P Compared With Eylea in Participants With Diabetic Macular Edema: Multicenter Double-Masked Randomized Phase 3 Study, <b>Susan Bressler, MD, FASRS</b>
1:11 PM	0.19 mg Fluocinolone Acetonide Implant Leads to Superior Vision, Anatomical, and Treatment Burden Outcomes in Eyes With Better Baseline Visual Acuity ( $\leq 20/40$ ), <b>Victor Gonzalez, MD</b>
1:15 PM	Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases, <b>Matthew Starr, MD</b>
1:21 PM	Discussion

- 1:29 PM Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study), **Rahul Khurana, MD, FASRS**
- 1:35 PM HORNBILL: Phase 1/2a Study of Safety and Early Response of BI-X in Patients With Diabetic Retinopathy and Diabetic Macular Ischemia Treated With Panretinal Photocoagulation, **Quan Nguyen, MD, MSc, FARVO, FASRS**
- 1:39 PM Association Between DRSS Changes and Visual/Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA, **Diana Do, MD, FASRS**
- 1:43 PM Discussion

**1:50-2:50 PM****Surgery Symposium 6**

Moderators: **Philip Ferrone, MD, FASRS** and **Vivienne Hau, MD, PhD**

- 1:50 PM Pathophysiology and Implications of Outer Retinal Corrugations in Rhegmatogenous Retinal Detachment, **Rajeev Muni, MD, MSC, FRCS(C), FASRS**
- 1:56 PM Repair of Progressive Retinal Detachment Complicating Degenerative Retinoschisis: Surgical Management and Outcomes in Phakic Eyes, **J. Fernando Arevalo, MD, PhD, FACS, FASRS**
- 2:02 PM Proliferative Choroidopathy: Clinical Presentation and Surgical Pearls in Complex Retinal Detachment with Advanced Proliferative Vitreoretinopathy, **Flavio Rezende, MD, PhD**
- 2:08 PM Retinal Detachment Associated With Giant Retinal Tears in 2 Stages Using Short-Term Tamponade With Perfluorocarbon Liquid Against Single-Stage Vitrectomy, **Naresh Kannan, MS, FNB(V R), MBA (H R), FASRS**
- 2:12 PM Surgical Outcomes of Rhegmatogenous Retinal Detachment in Patients 30 Years of Age or Younger at 3-Month, 1-Year, and 5-Year Follow-ups, **Samuel Minaker, MD, MSC**
- 2:18 PM Discussion
- 2:28 PM Localization of the Internal Limiting Membrane Flap After Macular Hole Surgery, **Homayoun Tabandeh, MD, FASRS**
- 2:32 PM Transretinal Subretinal Fluid Injection Technique for Refractory or Chronic Large Macular Holes, **Gregory Lee, MD**
- 2:36 PM Nasal Crowding and Nasal Tilting of the Macula After Epiretinal Membrane Surgery, **Kyu Hyung Park, MD**
- 2:42 PM Discussion

**2:50-3:30 PM****Break****3:30-4:10 PM****Surgery Symposium 7**

Moderators: **Timothy Murray, MD, MBA, FASRS** and **Audina Berrocal, MD, FASRS**

- 3:30 PM Dropless Vitrectomy Surgery for Epiretinal Membranes: Efficacy and Safety Compared to Standard of Care, **K. Chalam, MD, PhD, MBA, FRCS(C), FASRS**
- 3:36 PM Tips and Tricks in the Management of Complications Associated With Autologous Retinal Transplants, **Ryan Shields, MD**
- 3:42 PM Macular Hole Surgery Results With Long-Acting Gas Tamponade and Internal Limiting Membrane Removal, **John Thompson, MD**

3:48 PM	Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia, <b>Lejla Vajzovic, MD, FASRS</b>
3:54 PM	Scleral-Fixated Carlevalle IOL: The Ultimate Solution, <b>Stratos Gotzaridis, MBBS, MD</b>
3:58 PM	Discussion

---

#### 4:10-5:00 PM **Wet AMD 3 Symposium**

Moderators: **Arshad Khanani, MD, MA, FASRS** and **Elizabeth Rossin, MD, PhD**

4:10 PM	Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study, <b>W. Clark, MD, FASRS</b>
4:16 PM	Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD, <b>Neil Bressler, MD</b>
4:22 PM	Anti-VEGF Injection Prior Authorization Impacts on Retina Practices, <b>Sabin Dang, MD</b>
4:28 PM	Discussion
4:36 PM	Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept, <b>Mark Barakat, MD</b>
4:42 PM	Noninferiority of 1.7% Povidone-Iodine for Endophthalmitis Prophylaxis After Intravitreal Injections Compared With 5% Povidone-Iodine in an Office Setting, <b>Kamal Kishore, MD, MBBS</b>
4:46 PM	Endophthalmitis After Intravitreal Injections with 0.05% Aqueous Chlorhexidine vs 5% Povidone-Iodine as Ocular Antiseptics, <b>Murtaza Adam, MD</b>
4:52 PM	Discussion

---

#### 5:00-5:10 PM **Poster and Film Awards**

The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this Other activity (blended live and enduring material) for a maximum of 28.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **Disclosure Information**

In accordance with the ACCME's Standards for Commercial Support, ASRS required all individuals controlling the content of this CME activity to disclose all financial relationships with any ineligible companies. ASRS implemented mechanisms to mitigate those relevant financial relationships to prevent commercial bias. Please see the program booklet (our mobile meeting site) for disclosure information for all planners and teachers of this CME activity.

